| Lifestyle Drugs - New Opportunities in Rejuvenation Pharmaceuticals |
|---|
 |
| Publisher: | Nicholas Hall & Company |
| Year of publication: | 2001 |
| Type of publication: | Market report |
| Publisher's reference (if any): | N/A |
| Author(s): | Sreten Bogdanovic and Beata Langlands |
| Approximate page count: | 75 |
| Price when published: | £1,875 |
Remarks:
- Page numbers, where given, refer to the draft manuscript (which may differ from the published version).
- The copyright in this report is owned by the publisher, to whom any requests for copies should be addressed.
- This report is one of three modules; all modules are also available as a single volume, priced at £5,000.
|
TABLE OF CONTENTS
Page
About the authors v
Table of contents vii
List of tables xvii
EMERGING TRENDS SHAPING THE LIFESTYLE DRUGS MARKET
1 Patient-initiated-prescribing (PIP):
implications for the OTC market 1
2 Prospects for Rx-to-OTC switches of lifestyle drugs 1
2.1 The Rx-to-OTC movement 1
2.2 The likely role of consumers 2
2.3 The likely role of economic factors 4
2.4 Possible candidates for Rx-to-OTC switches 4
3 The advent of direct-to-customer (DTC) advertising 6
3.1 The rapidly growing US DTC advertising market 6
3.2 The prospects for DTC advertising in Europe 6
4 DTC advertising in the Internet healthcare market 7
5 The growth of online pharmacies 8
5.1 Five categories of the online pharmacy market 8
5.2 Limitations of traditional distribution channels 9
5.3 Advantages of online pharmacies 10
5.4 Challenges and risks facing online pharmacies 11
NEW OPPORTUNITIES IN REJUVENATION PHARMACEUTICALS
Rejuvenation Pharmaceuticals: Executive Summary 139
Chapter 17. Rejuvenation Pharmaceuticals:
Market & Technology Overview 141
17.1 The quest for a youthful appearance 141
17.2 Lifestyle drugs vs cosmetics and cosemceuticals 141
17.3 Age-related hair loss 142
17.3.1 Androgenetic alopecia 142
17.3.2 The normal hair cycle 142
17.3.3 The pathogenesis of androgenetic alopecia 143
17.3.4 Androgenetic alopecia in men 143
17.3.5 Androgenetic alopecia in women 145
17.3.6 Treatment of androgenetic alopecia 145
17.4 Skin ageing and photo-ageing 146
17.4.1 Skin biology 146
17.4.2 The ageing skin 147
17.4.3 Treatments for skin rejuvenation 148
Chapter 18. Topical Treatments for Hair Loss 150
18.1 Potassium channel agonists 150
18.1.1 Launched drug: Pharmacia's Rogaine 150
18.1.2 Drugs in development 151
18.2 Launched cosmeceutical: L'Oreal's Dercap 151
18.3 Launched cosmeceutical: Crinos' Foltene 152
18.4 Peptide copper complex compounds 152
18.5 Androgen receptor antagonists 153
18.6 Oestrogen receptor antagonists 153
18.7 Miscellaneous treatments 153
18.8 Control of gene expression 154
18.9 Preventing hair loss resulting from chemotherapy 154
Chapter 19. Oral Treatments for Hair Loss 156
19.1 5alpha-reductase Type II inhibitors 156
19.1.1 Launched drug: Merck & Co's Propecia 156
19.2 5alpha-reductase dual Type I/II inhibitors 157
Chapter 20. Treatments for Skin Rejuvenation 159
20.1 Injectable treatments 159
20.1.1 Launched products 159
20.1.2 Products in development 160
20.2 Topical treatments 160
20.2.1 Vitamin A 160
* Launched drug: Ortho Dermatological's Renova 160
* Launched cosmeceutical: retinol 160
20.3 Alpha and beta hydroxy acids 161
20.3.1 Launched cosmeceuticals 162
20.4 Vitamins C and E 163
20.4.1 Launched cosmeceuticals 163
20.5 Novel compounds in development 164
20.5.1 Anti-inflammatory 164
20.5.2 Miscellaneous 164
Chapter 21. Profiles of Selected Companies
in Rejuvenation Pharmaceuticals 166
Allergan Inc 166
Alteon Inc 167
AntiCancer Inc 168
Atlantic Technology Ventures Inc 169
Aventis 170
Biomatrix Inc 171
Biosphere Medical Inc 172
Cellegy Pharmaceuticals Inc 173
Dusa Pharmaceuticals Inc 174
GlaxoSmithKline 176
Johnson & Johnson 177
L'Oreal 179
Merck & Co 180
NeoStrata Company 182
OSI Pharmaceuticals Inc 183
Pharmacia Corporation 185
Phytopharm plc 188
Praxis Pharmaceuticals Inc 189
ProCyte Corporation 190
Q-Med A/B 192
Chapter 22. Rejuvenation Pharmaceuticals:
Market Analysis & Forecasts 193
22.1 World pharmaceutical market by region 2000 193
22.2 Hair loss markets 194
22.3 Skin rejuvenation markets 198
22.4 Overall rejuvenation market 199
Chapter 23. Rejuvenation Pharmaceuticals:
Trends & Opportunities 201
23.1 Lifestyle drugs for the "look good" generation 201
23.2 A huge potential market 201
23.3 Education before promotion of lifestyle drugs 201
23.4 Treatments for hair loss are inadequate 202
23.5 Sales may increase following Rx-to-OTC switches 203
23.6 A new focus on female pattern hair loss 203
23.7 Injectable skin treatments are evolving 203
23.8 Topical skin treatments are inadequate 203
23.9 Innovations tap into the cosmeceuticals market 204
23.10 Angiogenesis holds promise for hair growth 204
23.11 Control of gene expression offers a way forward 205
LIST OF TABLES
Table 13 Topical treatments for hair loss 155
Table 14 Oral treatments for hair loss 158
Table 15 Treatments for skin rejuvenation 165
Table 16 World pharmaceutical market by region 2000 193
Table 17 Selected world markets for hair loss
pharmaceuticals, 2000 and 2005 197
Table 18 Hair loss market segment predictions 2005 197
Table 19 Selected world markets for skin rejuvenation
pharmaceuticals, 2000 and 2005 200
|
